Benchling is a Cell Engineering & Bio-tools company founded in 2012 and based in San Francisco, United States. It is valued at $6.1B.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Nov 18, 2021 | Series F | $100M | $6.1B | Franklin Templeton, Altimeter Capital |
No articles ingested yet for Benchling. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
Benchling's cloud platform brings an electronic lab notebook, LIMS, molecular biology tools for CRISPR, primer and alignment design, and modules for biologics, bioprocess and in vivo studies into one system built on structured scientific data. Biopharma, agriculture, industrial biotech and materials teams use it to design sequences, record experiments and manage lab work from discovery through development. Much of the software is free for academic use.
Benchling AI puts agents and predictive models inside scientific workflows, grounded in the structured data the platform holds. Model Hub, launched on May 28, 2026, places models directly in workflows with outputs tied to the R&D record. Through a partnership announced on Jan. 8, 2026, Benchling customers can run Eli Lilly's TuneLab prediction models for antibodies and small molecules, trained on Lilly research data, and share data back for federated learning.
Benchling Automation, launched on May 28, 2026, is a hardware-agnostic system that links lab instruments, automation systems and scientific records into one loop. It dispatches runs to workcells or instruments and returns raw and analyzed data to the scientist's notebook entry, and it works with Benchling or any ELN or LIMS. Launch partners include HighRes, Automata, Ginkgo Bioworks, Celltrio, Opentrons and Hamilton, with direct ordering from Twist Bioscience, Adaptyv Bio and Ginkgo Bioworks.
Science Foundries, launched on Oct. 15, 2026, lets R&D teams run a scientific process end to end with AI agents and scientists working from the same data. Teams choose a goal such as producing proteins or optimizing a lead, set which steps agents run and where scientists must approve, and agents handle design, cloning and CRO orders, workcell instructions and QC, and analysis. Parabilis Medicines uses it for protein production, screening and lead optimization.
No recently verified openings are available right now. The company's careers page has the latest.
View all careers ↗